Takeda India named Top Employer in 2021
New Delhi: Takeda India has recently announced that the company has been named a Top Employer in 2021 by Top Employers Institute. This is also the fourth year in a row Takeda has received the prestigious global Top Employer status. Takeda also received four regional certifications for Asia Pacific, Europe, Latin America and Middle East.
Of the 38 Takeda local operating companies (LOCs) that were accredited this year, 24 are in Takeda's Growth & Emerging Markets Business Unit, including India.
"We are delighted to be named as Top Employer in India. At Takeda, empowering our people to shine is of utmost importance as we firmly believe that this is key in helping them give their best in our commitment to meet the needs of patients in the emerging markets," said Anoop Kamat, Head of HR. "Today's challenging COVID-19 pandemic environment calls for a heightened people-centric focus. In providing support for our employees, embracing diversity, and fostering a culture of trust, we can help create better health for people and a brighter future for the world."
Top Employers Institute CEO David Plink commented, "Takeda continues to show its dedication to its employees globally and locally, and we congratulate them for the fourth year in a row of global Top Employer certification."
The Top Employers Institute program certifies organizations based on the participation and results of their HR Best Practices Survey. This survey covers 6 HR domains consisting of 20 people- centric topics such as Career Development, Culture, Diversity & Inclusion, Learning, Sustainability, Values, Well-being and Work Environment. Established 30 years ago, the Institute has certified more than 1,600 Top Employers across five continents.
Takeda surpassed the requirements of Top Employers Institute, excelling in the areas of Values, Ethics & Integrity, Organizational Change, Leadership, Sustainability, Performance Management, and Engagement. The 38 LOCs that received accreditation in the geographic areas as defined by the Institute, are:
Africa: Algeria
Asia Pacific: Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand
Europe: Austria, Finland, France, Germany, Ireland, Italy, Kazakhstan, Poland, Portugal, Russia, Spain, Switzerland, Turkey, UK, and Ukraine
Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico and Peru
Middle East: Israel, Saudi Arabia, and United Arab Emirates
North America: United States
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.